Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer-Reference-Cited by-同舟云学术

Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

Published:2014-11-29 Issue:6 Volume:16 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

García-Martínez Elena,Gil Ginés Luengo,Benito Asunción Chaves,González-Billalabeitia Enrique,Conesa María Angeles Vicente,García Teresa García,García-Garre Elisa,Vicente Vicente,de la Peña Francisco Ayala

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/article/10.1186/s13058-014-0488-5/fulltext.html

Reference50 articles.

1. Chen AM, Meric-Bernstam F, Hunt KK, Thames HD, Oswald MJ, Outlaw ED, Strom EA, McNeese MD, Kuerer HM, Ross MI, Singletary SE, Ames FC, Feig BW, Sahin AA, Perkins GH, Schechter NR, Hortobagyi GN, Buchholz TA: Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004, 22: 2303-2312. 10.1200/JCO.2004.09.062.

2. Beriwal S, Schwartz GF, Komarnicky L, Garcia-Young JA: Breast-conserving therapy after neoadjuvant chemotherapy: long-term results. Breast J. 2002, 12: 159-164. 10.1111/j.1075-122X.2006.00225.x.

3. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L: Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012, 19: 1508-1516. 10.1245/s10434-011-2108-2.

4. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, et al: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014, 384: 164-172. 10.1016/S0140-6736(13)62422-8.

5. Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006, 24: 2019-2027. 10.1200/JCO.2005.04.1665.

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant chemotherapy-induced remodeling of human hormonal receptor-positive breast cancer revealed by single-cell RNA sequencing;Cancer Letters;2024-03

2. AKR1B10 Expression Characteristics in Hepatocellular Carcinoma and Its Correlation with Clinicopathological Features and Immune Microenvironment;2024-01-23

3. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer;BMC Cancer;2024-01-09

4. Immunogenic chemotherapy: great potential for improving response rates;Frontiers in Oncology;2023-12-06

5. Radiogenomic analysis of cellular tumor-stroma heterogeneity as a prognostic predictor in breast cancer;Journal of Translational Medicine;2023-11-25